[ad_1]
Original title: The United States urgently authorizes the new corona antibody cocktail to treat Trump once he receives this therapy Source: China Business News
For new coronary pneumonia that currently has no effective drug treatment, the antibody cocktail therapy developed by Regeneron Pharmaceuticals has been cleared by the US Food and Drug Administration (FDA) for emergency use. On November 21 local time, Regeneron announced that he is studying therapies for the new coronary pneumonia, using the antibody cocktail cascilizumab and iverdizumab (also known as REGN-COV2 or REGEN-COV2). A therapy has been cleared by the US Food and Drug Administration for emergency use.
These two monoclonal antibodies are used together to treat adults and patients with mild to moderate new coronary pneumonia, as well as pediatric patients who are at least 12 years old and weigh at least 40 kg. These patients have been tested twice for the new coronavirus and have developed a serious new coronavirus. High risk of pneumonia or hospitalization. Clinical evidence from Regeneron’s outpatient trial shows that patients who have not yet developed an autoimmune response or high viral load, such as the REGEN-COV2 monoclonal antibody, have the greatest benefit when given early after diagnosis.
US President Trump used the company’s “antibody cocktail therapy” after contracting the new coronavirus. After being released from the hospital, Trump also praised the therapy, promising to approve its emergency use and provide it to all Americans for free.
In an interview with the media, Trump also claimed that therapy is a “game changer” and “better than a vaccine.”
“Antibody cocktail therapy aims to neutralize the virus by using very effective antibodies to mimic the effects of a well-functioning immune system. Data from approximately 800 out-of-hospital patients show that within days of receiving therapy of antibody cocktail, Virus levels are significantly reduced, which is related to a significant reduction in the number of visits. For patients who are more likely to have a poor prognosis due to a high viral load, this benefit is the higher and the immune response is ineffective under the initial or pre-existing risk factors. So far, the analysis of the clinical trial did not find a variant that is resistant to cocktails, which is consistent with the results of our preclinical research, “he said. Dr. George D. Jankopulos, Regeneron’s President and Chief Scientific Officer.
The production of monoclonal antibodies is a complex, time-consuming, and time-consuming process. Regeneron hopes that by the end of November, he will prepare therapeutic doses of antibody cocktails for approximately 80,000 patients. By the first week of January 2021, approximately 200,000 patients will be ready for treatment. By the end of January 2021, a total of 300,000 patients prepare therapeutic agents.
“The antibody cocktail therapy is based on the company’s VelocImmune platform. It is made up of two highly active SARS-CoV-2 neutralizing antibodies (REGN10933 and REGN10987). It became famous because it was delivered to the President of the United States. With COVID-19 confirmed in early October, “But follow-up studies have found that it cannot effectively improve the condition of seriously ill hospitalized COVID-19 patients.” According to Wang Yuge, an American physician in immunology.
So far, more than 7,000 people have participated in clinical trials of antibody cocktail therapy.
Real-time statistics released by Johns Hopkins University in the United States show that at 08:40 on November 22, 2020 Beijing time, a total of 580,014,491 confirmed cases of new coronary patients worldwide, a total 1,378,866 deaths and a total of 191 confirmed countries and regions.
